Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Internship and Residency | 11 | 2024 | 695 | 3.560 |
Why?
|
| Pancreatic Neoplasms | 11 | 2017 | 315 | 2.010 |
Why?
|
| General Surgery | 4 | 2024 | 187 | 1.660 |
Why?
|
| Breast Neoplasms | 6 | 2024 | 1113 | 1.560 |
Why?
|
| Pancreatitis | 3 | 2020 | 99 | 1.260 |
Why?
|
| Carcinoma, Pancreatic Ductal | 7 | 2015 | 104 | 1.050 |
Why?
|
| Education, Medical, Graduate | 5 | 2024 | 299 | 1.010 |
Why?
|
| Pancreatectomy | 5 | 2016 | 85 | 1.010 |
Why?
|
| Endrin | 1 | 2024 | 2 | 0.930 |
Why?
|
| Mastectomy | 3 | 2024 | 54 | 0.910 |
Why?
|
| Nerve Block | 1 | 2024 | 40 | 0.880 |
Why?
|
| Social Media | 1 | 2021 | 110 | 0.650 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2019 | 26 | 0.650 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 139 | 0.620 |
Why?
|
| Databases, Factual | 2 | 2019 | 830 | 0.600 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 104 | 0.600 |
Why?
|
| Students, Medical | 1 | 2020 | 234 | 0.590 |
Why?
|
| Humans | 36 | 2024 | 58880 | 0.540 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2016 | 7 | 0.530 |
Why?
|
| Pancreas, Exocrine | 1 | 2016 | 12 | 0.530 |
Why?
|
| Retrospective Studies | 14 | 2024 | 5922 | 0.530 |
Why?
|
| Hemangioma | 1 | 2016 | 27 | 0.520 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 56 | 0.510 |
Why?
|
| Pancreatitis, Chronic | 1 | 2015 | 22 | 0.510 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2016 | 75 | 0.500 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 114 | 0.480 |
Why?
|
| Genetic Testing | 1 | 2015 | 132 | 0.470 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 267 | 0.460 |
Why?
|
| Postoperative Complications | 2 | 2019 | 1114 | 0.460 |
Why?
|
| Clinical Competence | 4 | 2024 | 669 | 0.440 |
Why?
|
| Adenocarcinoma, Mucinous | 4 | 2015 | 29 | 0.440 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 275 | 0.430 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2012 | 5 | 0.420 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 25 | 0.410 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2012 | 4 | 0.410 |
Why?
|
| Neurofibromatosis 1 | 1 | 2012 | 28 | 0.400 |
Why?
|
| Female | 20 | 2024 | 30581 | 0.370 |
Why?
|
| Burnout, Professional | 2 | 2023 | 118 | 0.360 |
Why?
|
| Surveys and Questionnaires | 5 | 2023 | 2563 | 0.340 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 36 | 0.340 |
Why?
|
| Stomach | 1 | 2010 | 84 | 0.340 |
Why?
|
| Pancreas | 1 | 2010 | 145 | 0.330 |
Why?
|
| Suture Techniques | 1 | 2010 | 84 | 0.330 |
Why?
|
| Hospital Units | 1 | 2008 | 8 | 0.310 |
Why?
|
| Gallstones | 1 | 2008 | 24 | 0.310 |
Why?
|
| Hospital Costs | 1 | 2008 | 118 | 0.290 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 2316 | 0.280 |
Why?
|
| Risk Factors | 5 | 2019 | 4975 | 0.270 |
Why?
|
| Patient Admission | 1 | 2008 | 184 | 0.270 |
Why?
|
| Internal Medicine | 2 | 2023 | 146 | 0.260 |
Why?
|
| Middle Aged | 12 | 2019 | 16134 | 0.260 |
Why?
|
| Cohort Studies | 4 | 2022 | 2429 | 0.250 |
Why?
|
| Male | 16 | 2023 | 27286 | 0.250 |
Why?
|
| Specialty Boards | 1 | 2024 | 12 | 0.240 |
Why?
|
| United States | 6 | 2024 | 7441 | 0.230 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2016 | 59 | 0.230 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 76 | 0.230 |
Why?
|
| Feedback | 1 | 2023 | 87 | 0.210 |
Why?
|
| Pain, Postoperative | 1 | 2024 | 125 | 0.210 |
Why?
|
| Educational Measurement | 1 | 2024 | 205 | 0.210 |
Why?
|
| Preoperative Care | 3 | 2019 | 171 | 0.210 |
Why?
|
| Pandemics | 3 | 2023 | 603 | 0.210 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 5046 | 0.200 |
Why?
|
| Prognosis | 4 | 2019 | 1561 | 0.190 |
Why?
|
| Motivation | 1 | 2023 | 266 | 0.190 |
Why?
|
| Robotic Surgical Procedures | 1 | 2023 | 90 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2013 | 301 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 2444 | 0.180 |
Why?
|
| Aged | 10 | 2017 | 13221 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2023 | 910 | 0.180 |
Why?
|
| Canada | 1 | 2020 | 143 | 0.180 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 207 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 925 | 0.170 |
Why?
|
| Treatment Outcome | 5 | 2017 | 5100 | 0.170 |
Why?
|
| Risk Assessment | 3 | 2020 | 1893 | 0.170 |
Why?
|
| Veins | 1 | 2020 | 61 | 0.170 |
Why?
|
| Adult | 9 | 2023 | 15609 | 0.170 |
Why?
|
| Inservice Training | 1 | 2020 | 81 | 0.170 |
Why?
|
| Surgical Oncology | 1 | 2019 | 3 | 0.170 |
Why?
|
| Research Design | 1 | 2023 | 561 | 0.170 |
Why?
|
| Certification | 1 | 2019 | 48 | 0.160 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 487 | 0.160 |
Why?
|
| Young Adult | 3 | 2016 | 4279 | 0.160 |
Why?
|
| Incidence | 2 | 2019 | 1226 | 0.160 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 98 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 32 | 0.160 |
Why?
|
| Learning | 1 | 2020 | 171 | 0.160 |
Why?
|
| Hepatectomy | 1 | 2019 | 58 | 0.160 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 15 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 12 | 0.150 |
Why?
|
| Mutation | 4 | 2015 | 2419 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 388 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 542 | 0.140 |
Why?
|
| Lymphoscintigraphy | 1 | 2016 | 6 | 0.140 |
Why?
|
| Sentinel Lymph Node | 1 | 2016 | 7 | 0.140 |
Why?
|
| Methylene Blue | 1 | 2016 | 22 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 37 | 0.140 |
Why?
|
| Curriculum | 1 | 2020 | 541 | 0.130 |
Why?
|
| Coloring Agents | 1 | 2016 | 54 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2020 | 485 | 0.130 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 34 | 0.130 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 11 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2014 | 19 | 0.120 |
Why?
|
| ras Proteins | 1 | 2015 | 78 | 0.120 |
Why?
|
| Time Factors | 3 | 2019 | 3544 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2019 | 411 | 0.120 |
Why?
|
| Diet | 1 | 2019 | 631 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 209 | 0.110 |
Why?
|
| Nomograms | 1 | 2013 | 11 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2013 | 5 | 0.110 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 31 | 0.110 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 315 | 0.110 |
Why?
|
| Melanoma | 1 | 2016 | 334 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 260 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 69 | 0.100 |
Why?
|
| New England | 2 | 2023 | 267 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 670 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 256 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 194 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 452 | 0.100 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 403 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 674 | 0.090 |
Why?
|
| Adolescent | 2 | 2012 | 5871 | 0.090 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2010 | 9 | 0.090 |
Why?
|
| Pancreatic Fistula | 1 | 2010 | 16 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2012 | 199 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 783 | 0.090 |
Why?
|
| Anastomosis, Surgical | 1 | 2010 | 94 | 0.090 |
Why?
|
| Carrier State | 1 | 2009 | 18 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1221 | 0.080 |
Why?
|
| Siblings | 1 | 2009 | 45 | 0.080 |
Why?
|
| Logistic Models | 2 | 2013 | 1245 | 0.080 |
Why?
|
| Pedigree | 1 | 2009 | 190 | 0.080 |
Why?
|
| Cholangiography | 1 | 2008 | 42 | 0.080 |
Why?
|
| Cholecystectomy | 1 | 2008 | 31 | 0.080 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2008 | 50 | 0.080 |
Why?
|
| Medicare | 1 | 2012 | 601 | 0.070 |
Why?
|
| Family | 1 | 2009 | 216 | 0.070 |
Why?
|
| Linear Models | 1 | 2008 | 418 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 286 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 294 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 1360 | 0.070 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 328 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2008 | 416 | 0.060 |
Why?
|
| Nipples | 1 | 2023 | 15 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2042 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2015 | 56 | 0.050 |
Why?
|
| Income | 1 | 2023 | 158 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 1446 | 0.050 |
Why?
|
| Personnel Selection | 1 | 2022 | 45 | 0.050 |
Why?
|
| Self Report | 1 | 2023 | 365 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 41 | 0.050 |
Why?
|
| Students | 1 | 2022 | 207 | 0.040 |
Why?
|
| Mammography | 1 | 2021 | 270 | 0.040 |
Why?
|
| Lung | 1 | 2023 | 819 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 73 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 34 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 66 | 0.030 |
Why?
|
| Mice | 1 | 2010 | 10194 | 0.030 |
Why?
|
| Chromogranins | 1 | 2015 | 12 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 41 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 890 | 0.030 |
Why?
|
| Observer Variation | 1 | 2014 | 201 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 248 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 208 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 240 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 402 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 446 | 0.030 |
Why?
|
| SEER Program | 1 | 2012 | 65 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 893 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 1090 | 0.020 |
Why?
|
| Health Services | 1 | 2012 | 85 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 205 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1030 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 9 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1537 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 73 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 177 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 113 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 1126 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3077 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 1272 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 19498 | 0.010 |
Why?
|